Patent ID: 6395750
Filing Date: 2002-05-28
Classification: A61K,A61P,C07D

Abstract:
A method for the treatment of breast or prostrate cancers in a mammal comprising administration to said mammal of an amount effective therefor of a compound of the formula (I) whereinA is selected from the group consisting of OR41 and NR42 R43 wherein R41 is selected from the group consisting of hydrogen and pharmaceutically acceptable inorganic cations, and organic cations; and CORA wherein RA is selected from the group consisting of alkyl and aryl groups; R42 and R43 are the same and different and selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, and cyclopropyl, or R42 is CORB wherein RB is selected from C1-C4-alkyl, or CORB is a 2-acyloxymethylbenzoyl group whereinRC is selected from the group consisting of methyl, ethyl, phenyl and benzyl; R43 is as defined above; R is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; with the proviso that R is not hydrogen when A is OR41; Râ€² is selected from the group consisting of hydrogen, methyl, methoxy, fluoro, chloro, bromo, cyano, trifluoromethyl, and OCHxFy, â€ƒwherein x=0-2, y=1-3 with the provisos that x+y=3; and that Râ€² is not hydrogen when R is methyl and A is OR41;Râ€³ is selected from the group consisting of hydrogen, fluoro and chloro, with the proviso that Râ€³ is selected from fluoro and chloro only when Râ€² is selected from fluoro and chloro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, fluoro, chloro, bromo, dimethylamino OCHxFy, and OCH2CHxFy â€ƒwherein x=0-2, y=1-3 with the provisos that x+y=3 and that R5 is not fluoro when A is OR41; and that R5 is hydrogen only when A is NR42 R43 and Râ€² is trifluoromethyl;R6 is hydrogen; or R5 and R6 taken together are methylenedioxy; or any tautomer thereof.